Non-Small Cell Lung Cancer (NSCLC)

At the BIG10 CRC Summit, Mingjia Li, MD, outlined how pre-operative hemoglobin may signal treatment response in resectable NSCLC.

The therapeutic cancer vaccine OSE2101 combined with either docetaxel or nivolumab met the primary end point of 1-year overall survival in the Combi-TED trial.

The oral KRAS G12D inhibitor VS-7375 produced responses in pancreatic, colorectal, and lung cancers in the phase 1/2 TARGET-D 101 trial.

The phase 3 FURVENT trial showed an objective response rate benefit with firmonertinib in EGFR exon 20 insertion–mutant NSCLC.

Data from the REZILIENT3 trial support the NDA for zipalertinib plus chemotherapy for those with NSCLC harboring EGFR exon 20 insertion mutations.

Three nurses discuss the differences in the care and education required for patients with first-line EGFR-mutated non–small cell lung cancer.

David R. Gandara, MD, explains what makes KRAS G12C biologically distinct from other KRAS subtypes in NSCLC immunotherapy response.

Xiuning Le, MD, PhD, weighs sevabertinib against zongertinib and trastuzumab deruxtecan in HER2-mutant non–small cell lung cancer.

Xiuning Le, MD, PhD, explains how oncologists should approach HER2 biomarker testing following sevabertinib’s frontline approval in non–small cell lung cancer.

Subcutaneous amivantamab is safer and more convenient for patients compared with the intravenous formulation, according to Misako Nagasaka, MD, PhD.

Investigators are evaluating cesalatamig among patients with advanced cancer in the international phase 1/2 BiPAVE-001 trial.

The FDA granted fast track designation to the oral pan-KRAS inhibitor KST-6051 for patients with KRAS-mutant advanced or metastatic solid tumors.

Based on updated data from the TRUST-1 trial, a sNDA for taletrectinib has been approved by the FDA for patients with TKI-naive ROS1+ NSCLC.

Misako Nagasaka, MD, PhD, explains how subcutaneous amivantamab’s shorter administration time benefits patients and infusion centers.

Misako Nagasaka, MD, PhD, discusses PALOMA-2’s 70% 3-year survival rate compared with historical MARIPOSA data for intravenous amivantamab.

The OMNI-EGFR inhibitor BH-30643 produced a 45% objective response rate among patients with EGFR C797S–positive disease in the phase 1/2 SOLARA trial.

New data on antibody drug conjugates and extended survival follow-ups may inform clinical decision-making surrounding non–small cell lung cancer.

ALK rearrangements are uncommon but actionable oncogenic drivers in non–small cell lung cancer.

The FDA has granted accelerated approval to sevabertinib for metastatic non-squamous NSCLC with HER2 TKD activating mutations based on results from the SOHO-01 trial.

In a phase 1/2 study, daraxonrasib produced objective responses in more than 30% of patients with previously treated RAS-mutant NSCLC.

Savolitinib/osimertinib significantly improved progression-free survival vs osimertinib alone as first-line treatment in the phase 3 SANOVO trial.

Japan’s MHLW approved sevabertinib for HER2-mutant advanced or recurrent NSCLC across all lines of therapy based on phase 1/2 SOHO-01 data.

Detailed findings from the phase 3 DESTINY-Lung04 trial will be presented at a future medical meeting and shared with regulatory health authorities.

The phase 3 eVOLVE-Lung02 trial will halt after an independent committee concluded that volrustomig plus chemotherapy was unlikely to improve survival.

Data from the SAFFRON trial may represent a critical advance in the management of EGFR-mutated NSCLC with MET-driven resistance.